ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,103Medicare Part D Prescriptions Filled, Including Refills

Rank: 315 out of 1692

$381K Total Retail Price of All Prescriptions

Rank: 428 out of 1692

295 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
61% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Virginia
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 295 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

10% of this provider’s 295 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 7,462 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

17% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Virginia
SIMVASTATIN 358 334 1 1
AMLODIPINE BESYLATE 280 271 2 3
LISINOPRIL 272 242 3 2
METFORMIN HCL 227 199 4 8
OMEPRAZOLE 209 185 5 5
LEVOTHYROXINE SODIUM 188 185 6 4
NAMENDA 181 181 7 50
FUROSEMIDE 166 166 8 7
WARFARIN SODIUM 153 153 9 14
MIRTAZAPINE 139 139 10 53
GENERLAC 139 139 10 248
POTASSIUM CHLORIDE 135 135 12 20
HYDROCODONE-ACETAMINOPHEN 132 110 S3 13 6
LOSARTAN-HYDROCHLOROTHIAZIDE 129 121 14 38
ATENOLOL 128 128 15 15
LOSARTAN POTASSIUM 124 103 16 17
METOPROLOL TARTRATE 123 109 17 10
CARVEDILOL 123 123 17 24
DONEPEZIL HCL 108 104 19 29
POLYETHYLENE GLYCOL 3350 105 105 20 64
LANTUS 101 94 21 57
TRAMADOL HCL 98 98 22 16
TAMSULOSIN HCL 88 81 23 31
SERTRALINE HCL 86 82 24 22
ZOLPIDEM TARTRATE 84 76 25 23
PRAVASTATIN SODIUM 83 80 26 12
ISOSORBIDE MONONITRATE ER 83 83 26 55
INSULIN SYRINGE 82 82 28 93
DIVALPROEX SODIUM 81 56 29 97
NEXIUM 78 66 30 25
QUETIAPINE FUMARATE 77 77 31 62
AZITHROMYCIN 73 67 32 34
GLYBURIDE 67 66 R 33 82
PERMETHRIN 66 64 34 299
NYSTATIN-TRIAMCINOLONE 64 48 35 220
TRIAMTERENE-HCTZ 61 60 36 61
GLYBURIDE-METFORMIN HCL 61 61 R 36 157
SPIRONOLACTONE 61 61 36 74
ATORVASTATIN CALCIUM 59 58 39 11
ALLOPURINOL 59 52 39 30
TRAZODONE HCL 58 58 41 33
PREDNISONE 57 55 42 35
RISPERIDONE 54 34 43 77
CLOPIDOGREL 52 40 44 43
ADVAIR DISKUS 52 30 44 45
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 14, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.